-
Founded in:
2000-09-30 -
Country:
China -
Address:
West of Quanfa Road, Wuqing Development Zone, Tianjin New Technology Industrial Park -
Tax NO.:
9112000010409702XT -
Registered Funds:
3,004,154,837 yuan -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Cetirizine dihydrochloride |
This product is a selective histamine H1 receptor antagonist. Animal experiments show that this product has no obvious anticholinergic and anti-5-hydroxytryptamine effects, and is not easy to pass through the blood-cerebrospinal fluid barrier to act on the central H1 receptor. When used clinically, the central inhibitory effect is relatively mild.
More
This product is a selective histamine H1 receptor antagonist. Animal experiments show that this product has no obvious anticholinergic and anti-5-hydroxytryptamine effects, and is not easy to pass through the blood-cerebrospinal fluid barrier to act on the central H1 receptor. When used clinically, the central inhibitory effect is relatively mild. |
83881-52-1 | 56 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| tremella polysaccharide |
This product is a basidiomycete polysaccharide immunopotentiator, which has the effect of improving the body's immune function and increasing white blood cells. Animal experimental studies have shown that it can treat leukocytopenia caused by hydrochloric acid nitrogen mustard and cyclophosphamide in rabbits; it can promote the recovery of hematopoietic function in mice, dogs, and monkeys after gamma ray irradiation and improve the survival rate; it can significantly improve the phagocytic function of mouse reticuloendothelial cells, increase the number of monkey peripheral lymphocytes, the formation rate of E rosettes and EAC rosettes in macaque peripheral blood, increase the level of immunoglobulins and serum total complement, and has a preventive and therapeutic effect on leukocytopenia in rats caused by cyclophosphamide; it has the effect of promoting antibody production in normal and tumor-bearing mice, can activate spleen function, and enhance specific and non-specific immune responses.
More
This product is a basidiomycete polysaccharide immunopotentiator, which has the effect of improving the body's immune function and increasing white blood cells. Animal experimental studies have shown that it can treat leukocytopenia caused by hydrochloric acid nitrogen mustard and cyclophosphamide in rabbits; it can promote the recovery of hematopoietic function in mice, dogs, and monkeys after gamma ray irradiation and improve the survival rate; it can significantly improve the phagocytic function of mouse reticuloendothelial cells, increase the number of monkey peripheral lymphocytes, the formation rate of E rosettes and EAC rosettes in macaque peripheral blood, increase the level of immunoglobulins and serum total complement, and has a preventive and therapeutic effect on leukocytopenia in rats caused by cyclophosphamide; it has the effect of promoting antibody production in normal and tumor-bearing mice, can activate spleen function, and enhance specific and non-specific immune responses. |
9075-53-0 | 0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Fasudil hydrochloride |
Fasudil hydrochloride is a protein kinase inhibitor, i.e., an intracellular calcium ion antagonist. It dilates blood vessels and inhibits vasospasm by blocking the final stage of vasoconstriction, myosin light chain phosphorylation.
More
Fasudil hydrochloride is a protein kinase inhibitor, i.e., an intracellular calcium ion antagonist. It dilates blood vessels and inhibits vasospasm by blocking the final stage of vasoconstriction, myosin light chain phosphorylation. |
105628-07-7 | 54 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Fasudil hydrochloride |
|
105628-07-7 | 54 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Simvastatin |
This product itself is inactive. After oral absorption, its hydrolysis product competitively inhibits the rate-limiting enzyme hydroxymethylglutaryl coenzyme A reductase in the cholesterol synthesis process in the body, reducing the synthesis of cholesterol and increasing the synthesis of low-density lipoprotein receptors. The main site of action is in the liver, resulting in lower blood cholesterol and low-density lipoprotein cholesterol levels, moderately lower serum triglyceride levels and increased blood high-density lipoprotein levels. This has an effect on the prevention and treatment of atherosclerosis and coronary heart disease.
More
This product itself is inactive. After oral absorption, its hydrolysis product competitively inhibits the rate-limiting enzyme hydroxymethylglutaryl coenzyme A reductase in the cholesterol synthesis process in the body, reducing the synthesis of cholesterol and increasing the synthesis of low-density lipoprotein receptors. The main site of action is in the liver, resulting in lower blood cholesterol and low-density lipoprotein cholesterol levels, moderately lower serum triglyceride levels and increased blood high-density lipoprotein levels. This has an effect on the prevention and treatment of atherosclerosis and coronary heart disease. |
79902-63-9 | 63 |